Adial Pharmaceuticals, Inc. (ADIL)
| Market Cap | 94.68M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.08M |
| Shares Out | 20.45M |
| EPS (ttm) | -1.04 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,051,451 |
| Open | 4.66 |
| Previous Close | 4.39 |
| Day's Range | 4.41 - 5.08 |
| 52-Week Range | 1.20 - 5.08 |
| Beta | 0.70 |
| Analysts | n/a |
| Price Target | 10.00 (+114.1%) |
| Est. Earnings Date | Nov 11, 2021 |
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.
Financial Performance
Financial StatementsNews
Adial CEO William Stilley Invited to Participate in Maxim Group's Virtual Panel Series Conference: “Disruptors in the...
CHARLOTTESVILLE, Va., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing th...
Adial Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
CHARLOTTESVILLE, Va., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing th...
Adial Pharmaceuticals Exceeds Enrollment Target in ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients with A...
ONWARD trial enrollment closed; trial completion expected in Q1 2022 ONWARD trial enrollment closed; trial completion expected in Q1 2022
Adial Pharmaceuticals Reaches Full Enrollment Target for ONWARD™ Phase 3 Trial of AD04 for the Treatment of Patients ...
On track for trial completion in the first quarter of 2022
Adial Pharmaceuticals to Host Conference Call Today at 11AM Eastern to Provide Clinical Update and Discuss Positive B...
CHARLOTTESVILLE, Va., Aug. 20, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...
Adial Pharmaceuticals Schedules Conference Call to Provide Clinical Update and Discuss Positive Business Developments
CHARLOTTESVILLE, Va., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...
Adial Pharmaceuticals Awarded U.S. and International Patents for the Treatment Of Alcohol and Opioid Use Disorders Us...
CHARLOTTESVILLE, Va., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...
Adial Pharmaceuticals Announces Closing of $5 Million Private Placement Priced at a Premium to Market
Financing fully funds ONWARD™ Phase 3 trial until data read-out Financing fully funds ONWARD™ Phase 3 trial until data read-out
Adial Pharmaceuticals Reports CEO Op-Ed Featured on Nasdaq.com
CHARLOTTESVILLE, Va., July 29, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...
Adial Announces Positive Pre-Clinical Data for its Adenosine Pain Platform
Data merits further testing for pain reduction as a possible alternative to opioids
Adial Announces $5,000,000 Above Market Private Placement at $3.00 Per Share
CHARLOTTESVILLE, Va., July 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...
The Phase 3 ONWARD™ Trial Meets its Screening Target and Nears Enrollment Completion
Study Drug Continues to Appear to be Well-Tolerated
Adial Joins Russell Microcap® Index
CHARLOTTESVILLE, Va., June 28, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...
FDA Denies Adial Pharma's Fast Track Request For AD04 in Alcohol Use Disorder
Adial Pharmaceuticals Inc (NASDAQ:ADIL) has received notice from the FDA that its request for Fast Track Designation for AD04 in Alcohol Use Disorder has been denied at this time. The FDA stated that th...
Adial Pharmaceuticals Provides Regulatory and Development Update
CHARLOTTESVILLE, Va., June 24, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...
Top 10 Biotech Penny Stocks to Watch in July 2021
Are these the best biotech penny stocks to watch next month? Here's 5 more for your list The post Top 10 Biotech Penny Stocks to Watch in July 2021 appeared first on Penny Stocks to Buy, Picks, News and...
Adial Pharmaceuticals Plans to Enter Genetic Testing Market Following Allowance of U.S. Patent for Genetic Diagnostic...
The Company believes the genetic companion diagnostic test for AD04 for Alcohol Use Disorder represents a multi-billion dollar potential market opportunity The Company believes the genetic companion dia...
Adial Pharmaceuticals Comments on Article in ‘The Atlantic,' Highlighting the Second Pandemic of Addiction
CHARLOTTESVILLE, Va., June 07, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...
Adial Announces Funding of Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
CHARLOTTESVILLE, Va., June 03, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing the...
Adial Pharmaceuticals Featured on Multiple News Broadcasts Nationwide Regarding the Second Pandemic of Alcohol Use Di...
CHARLOTTESVILLE, Va., May 18, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments fo...
Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel
Discusses long-term effects of COVID-19 pandemic on mental health and addiction Discusses long-term effects of COVID-19 pandemic on mental health and addiction
Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
CHARLOTTESVILLE, Va., March 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing th...
Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion
CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments f...
Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants
CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the developmen...
Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...